4D Molecular Therapeutics (FDMT) Stock Forecast & Price Target

$8.45

-0.21 (-2.42%)

(As of 10/17/2024 ET)

4D Molecular Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 10 Analyst Ratings

Sell
0

Hold
1

Buy
9

Based on 10 Wall Street analysts who have issued ratings for 4D Molecular Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 1 has given a hold rating, and 9 have given a buy rating for FDMT.

Consensus Price Target

$45.25
435.50% Upside

According to the 10 analysts' twelve-month price targets for 4D Molecular Therapeutics, the average price target is $45.25. The highest price target for FDMT is $81.00, while the lowest price target for FDMT is $32.00. The average price target represents a forecasted upside of 435.50% from the current price of $8.45.

Get the Latest News and Ratings for FDMT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for 4D Molecular Therapeutics and its competitors.

FDMT Analyst Ratings Over Time

Type	Current Forecast 10/18/23 to 10/17/24	1 Month Ago 9/18/23 to 9/17/24	3 Months Ago 7/20/23 to 7/19/24	1 Year Ago 10/18/22 to 10/18/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	10 Buy rating(s)	10 Buy rating(s)	6 Buy rating(s)
Hold	1 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$45.25	$43.63	$43.63	$37.50
Forecasted Upside	435.50% Upside	169.96% Upside	202.95% Upside	260.23% Upside
Consensus Rating	Moderate Buy	Buy	Buy	Moderate Buy

Trump or Kamala? It may come down to this strange twist… (Ad)

Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? To uncover the full story and learn how you can potentially profit from it...

watch my new documentary here.

FDMT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

FDMT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

4D Molecular Therapeutics Stock vs. The Competition

Type	4D Molecular Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.90	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	435.50% Upside	12,627.93% Upside	6.31% Upside
News Sentiment Rating	Neutral News See Recent FDMT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/23/2024	Cantor Fitzgerald 3 of 5 stars	J. Schimmer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
9/19/2024	Chardan Capital 2 of 5 stars		Boost Target	Buy ➝ Buy	$38.00 ➝ $39.00	+191.70%
9/19/2024	Leerink Partners 1 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$40.00 ➝ $36.00	+114.03%
9/19/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00	+114.03%
7/22/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$40.00 ➝ $40.00	+174.16%
7/18/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$63.00 ➝ $40.00	+135.71%
Get the Latest News and Ratings for FDMT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
4/15/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight
4/1/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$30.00 ➝ $58.00	+89.67%
2/7/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$81.00	+143.90%
10/18/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Foroohar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
6/8/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$28.00 ➝ $33.00	+60.19%
4/13/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Perform	$14.00 ➝ $13.00	-14.25%
11/14/2022	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$32.00 ➝ $45.00	+238.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 11:42 PM ET.

FDMT Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for 4D Molecular Therapeutics is $45.25, with a high forecast of $81.00 and a low forecast of $32.00.
: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 4D Molecular Therapeutics in the last twelve months. There is currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FDMT shares.
: According to analysts, 4D Molecular Therapeutics's stock has a predicted upside of 435.50% based on their 12-month stock forecasts.
: Over the previous 90 days, 4D Molecular Therapeutics's stock had 1 downgrade by analysts.
: 4D Molecular Therapeutics has been rated by research analysts at Cantor Fitzgerald, Chardan Capital, HC Wainwright, Leerink Partners, and Royal Bank of Canada in the past 90 days.
: Analysts like 4D Molecular Therapeutics more than other "medical" companies. The consensus rating score for 4D Molecular Therapeutics is 2.90 while the average consensus rating score for "medical" companies is 2.79. Learn more on how FDMT compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Trump or Kamala? It may come down to this strange twist… (Ad)

Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? To uncover the full story and learn how you can potentially profit from it...

watch my new documentary here.

This page (NASDAQ:FDMT) was last updated on 10/17/2024 by MarketBeat.com Staff

From Our Partners